/
ALMDP.PA
No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Medesis Pharma S.A.
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
www.medesispharma.com- Employees
- 10
- IPO / List date
- Feb 12, 2021
- HQ
- FR
Held by traders on TradeandTell
No one on the platform currently holds ALMDP.PA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ALMDP.PA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALMDP.PA yet.